



For immediate release

Seinäjoki, Finland 28.8.2024

EEVIA HEALTH RECEIVES MULTIPLE SALES ORDERS FOR C. KSEK 1 000 (KEUR 92).

Eevia Health PLC ("Eevia" or "The Company") received several sales orders for extracts totaling KEUR 92 from various European, Australian, and American customers.¹

Several customers placed a total of KEUR 90 in sales orders. Three orders came from one distributor, NutriOriginal (New Jersey, US): KEUR 18 for Feno-Chaga Organic, a mushroom extract; KEUR 11 for Feno-Myrtillus 25 Organic (Bilberry Extract); and KEUR 15 for Feno-Chaga NFS Organic.

Another sales order is from the Australian distributor Ingredients Plus for Feno-Sambucus 17 (Elderberry Extract), KEUR 18. The end customer is an Australian brand owner focusing on mums' and children's health solutions.

Furthermore, a French trading partner has ordered Feno-Myrtillus 25 (Bilberry Extract), KEUR 30. The trading partner is known for delivering high-quality natural products and has repeat business for Eevia's highly concentrated bilberry extracts. The end customer is a large supplement brand.

Eevia has the products in stock so that they can be delivered immediately without purchasing raw materials, which is why they are strong contributions to cash flow. These orders are repeat orders, and Eevia expects further repeat orders in the future from the same customers.

"We see a spike in the interest for Feno-Chaga organic, and it is a product with good profitability for us, so we are especially pleased to see conversion to sales orders for this SKU. Dietary supplements based on mushrooms are growing fast in key markets. Various agencies estimate 10 to 15% growth (CAGR 2025 -2030) for mushroom-derived products. Chaga is known as the "King of Mushrooms". Feno-Chaga is one product we have conducted a human clinical trial on with interesting results for stress management and sports performance." Says Anna-Maija Vanhatalo, Customer Service Manager at Eevia Health

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com

Telephone: +358 400 22 5967

¹ Eevia has a threshold at minimum KEUR 50 for publishing new sales orders, but will publish when we have multiple orders totaling more than KEUR 50.



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) [EEVIA](#).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.